Innovative Pharmaceuticals on the Path to Progress. What is the Best Way to Stimulate the Industry’s Development?

5 June, 14:30–16:00 Congress Centre, zone A, 3rd floor, conference hall A
Broadcast
The pharmaceutical industry is one of the most rapidly developing sectors of the Russian economy. In the current times, pharmaceuticals manufacturers, particularly high-tech Russian companies or ‘national champions’ as they are called, have become the main driving force in the development of innovative Russian pharmaceuticals due to their substantial investments in research and development and solid performance during the COVID-19 pandemic and success in implementing priority import substitution projects. However, the further development of the industry still hinges on improved measures for the funding of new developments and tools to provide government support to pharmaceutical companies. Grants, concessional loans, equity investments, and public listings are all effective funding tools that could be used to develop cutting-edge projects in the pharmaceutical industry, which would improve business efficiency and potentially reduce innovation costs. What are some of the best domestic and international practices and cases that exist today for funding pharmaceutical innovations? How will digital financial assets and investment platforms help the Russian pharmaceutical sector generate additional investment for development? How can we enhance the appeal of pharmaceutical companies and reduce risks for investors? How should we fund the ‘valley of death’ in the development of new drugs? What factors and mechanisms are crucial to building an innovative environment that will support an increase in the share of high-quality domestic drugs on the Russian market, including as part of the process of phasing out imports?

Broadcast

Image